Skip to main content

Table 3 CIN2+ case detection by different combinations of HPV testing methods and sampling media

From: Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening

ID no. Pathological result HC2 (Rlu/PC) careHPV™ (Rlu/PC) Cobas® 4800
Liquid FTA Liquid FTA Liquid FTA
447 CIN2 0.20a 181.73 0.42a 17.11 POS POS
445 CIN2 99.90 22.42 51.31 28.50 POS POS
444 CIN3 472.51 650.36 170.00 173.28 POS POS
442 CIN2 675.40 325.26 117.93 140.85 POS POS
448 CIN2 451.36 43.57 104.47 34.00 POS POS
441 CIN2 2003.50 19.03 150.79 37.03 POS POS
446 CIN2 4.26 0.28a 1.39 0.58a POS POS
443 CIN2 463.18 150.22 80.80 89.48 POS POS
450 CIN2 1031.00 92.23 100.65 61.33 POS POS
240 HCGIN 1.05 1.34 0.29a 0.78a NEGa NEGa
288 CIN3 26.62 1.42 20.65 3.71 POS POS
344 CIN2 5.00 50.89 2.68 29.71 POS POS
  1. CIN2 cervical intraepithelial neoplasia grade 2, CIN3 cervical intraepithelial neoplasia grade 3, HCGIN high grade cervical glandular intraepithelial neoplasia, FTA Whatman Indicating FTA Elute® card, HC2 Hybrid capture 2, NEG negative result, POS positive result, RLU/PC the ratio of relative light units to standard positive control, cut-point: 1.0
  2. aCIN2+ case failed to be detected
\